

Immunological and clinical consequences of sustained low-level viremia in patients receiving HAART

Tanya Welz¹, Loveleen Bansi², Philippa Easterbrook¹ and Caroline Sabin² on behalf of the UK Collaborative HIV Cohort Study (CHIC)

1. Guy's, Kings and St. Thomas's School of Medicine, London, UK

2. Royal Free and University College Medical School, London, UK



Objectives

- To determine the incidence of SLLV amongst patients on HAART who initially achieve an undetectable viral load ($VL \leq 500$ cps/ml)
- To describe the virological, immunological and clinical outcomes in patients with SLLV
- To identify epidemiological correlates of high-level virological failure ($VL > 20,000$ cps/ml) or return to undetectable VL (≤ 500 cps/ml) amongst patients with SLLV

Patients and Methods

- Eligible individuals had a VL ≤ 500 cps/ml on 2 occasions at least 3 months apart on HAART
- SLLV was defined as a VL of 501-20,000 cps/ml over ≥ 6 months (3+ measurements) in patients with initial undetectable VL
- SLLV ended when a patient's VL moved outside this range or when the patient stopped HAART; only first episodes of SLLV were considered for this analysis
- For this analysis, follow-up of those who did not experience high-level virological failure was censored at:
 - a) First VL ≤ 500 cps/ml (if VL became undetectable)
 - b) VL at stopping HAART (if patient came off HAART)
 - c) 12 months after last VL (if patient lost to follow-up)
 - d) Last VL (if patient had continuing SLLV)

Table 1: CD4 and virological changes during SLLV

	Continuing SLLV N=48	VL >20,000 N=85	VL ≤500 N=143	Stopped HAART N=23	P- Value*
Duration of SLLV (mths)	14.7 (9.2,30.1)	13.5 (10.3,20.5)	10.3 (7.7,13.8)	12.5 (9.4,18.1)	<0.001
Treatment change during SLLV	13 (27.1%)	44 (51.8%)	103 (72.0%)	19 (82.6%)	<0.001
Median (IQR) CD4 count (cells/mm³)					
At start of SLLV	355 (219,490)	298 (220,533)	315 (210,440)	426 (190,510)	
At end of SLLV	311 (218,450)	336 (221,490)	335 (232,453)	354 (270,478)	
Change per 6 mths	6.6 (-16.2,19.7)	-27.7 (-66.4,11.1)	19.6 (-4.4,43.6)	-8.4 (-83.6,66.8)	<0.001
Median (IQR) VL (cps/ml)					
At start of SLLV	3.24 (2.98,3.53)	3.20 (2.95,3.55)	3.08 (2.85, 3.38)	3.30 (2.90, 3.70)	
At end of SLLV	3.48 (3.18,3.74)	3.77 (3.29,-4.01)	3.29 (3.00, 3.63)	3.57 (2.81, 3.69)	
Log change per 6 mths	0.07 (0.20,0.11)	0.37 (0.31,0.43)	-0.15 (-0.19, -0.10)	0.08 (-0.02, 0.19)	<0.001

Viral load at end of SLLV refers to the last viral load prior to moving out of the range 501-20000 copies/ml.

*P-Values comparing the 4 groups are obtained using Chi-squared and Mann Whitney Tests.

**Treatment change made prior to stopping HAART

Table 2: Results from a Cox regression analysis of factors associated with return to undetectable ≤ 500 cps/ml) as an outcome of SLLV

Variables		Hazard Ratio	95% CI	P-Value
Male sex		3.53	1.19-10.45	0.02
Age at start of SLLV (per 5 years)		1.15	1.03-1.29	0.02
Ethnicity (compared to white)	Black	0.43	0.23-0.81	0.008
	Other	0.74	0.47-1.16	0.19
Homosexual exposure		0.49	0.30-0.81	0.005
Onset of SLLV after 2000		2.02	1.36-3.00	0.0005
Treatment change		6.94	4.77-10.11	0.0001
Total no. of PIs (per 1 drug increase)		1.22	1.01-1.45	0.03
Time from HAART initiation to SLLV (Per month)		0.97	0.95-0.99	0.005
Time from UD to SLLV (Per month)		1.05	1.02-1.08	0.0003
VL at start of SLLV (Per log copies/ml)		0.42	0.26-0.67	0.0004

Summary

- SLLV is a rare phenomenon; using our strict definition, only 4.9% of patients who achieved viral suppression experienced an episode of SLLV
- CD4 changes over SLLV were minimal in most cases and were not significant
- The strongest predictors of regaining an undetectable VL after SLLV were treatment change during SLLV (OR=6.9), male sex (OR=3.5) and onset of SLLV after 2000 (OR= 2.0)
- There were no significant adverse clinical or immunological consequences of SLLV in the medium term. However, patients with ongoing SLLV had smaller CD4 cell gains than those who returned to VL_≤500 copies/ml